Systematic review: third-line susceptibility-guided treatment for Helicobacter pylori infection (Q26745727)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27366212%20AND%20SRC:MED&resulttype=core&format=json

17 March 2020

1 reference

1 reference

title

Systematic review: third-line susceptibility-guided treatment for Helicobacter pylori infection (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27366212%20AND%20SRC:MED&resulttype=core&format=json

17 March 2020

0 references

1 reference

Helicobacter pylori infectious disease

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27366212%20AND%20SRC:MED&resulttype=core&format=json

17 March 2020

Xavier Calvet

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27366212%20AND%20SRC:MED&resulttype=core&format=json

17 March 2020

10

Javier P Gisbert

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27366212%20AND%20SRC:MED&resulttype=core&format=json

17 March 2020

2

Sheila López-Góngora

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27366212%20AND%20SRC:MED&resulttype=core&format=json

17 March 2020

5

Albert Villoria

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27366212%20AND%20SRC:MED&resulttype=core&format=json

17 March 2020

6

Mireia Baylina

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27366212%20AND%20SRC:MED&resulttype=core&format=json

17 March 2020

Jordi Sanchez-Delgado

7

object named as

Jordi Sanchez-Delgado

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27366212%20AND%20SRC:MED&resulttype=core&format=json

17 March 2020

Victor García-Hernando

9

object named as

Victor García-Hernando

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27366212%20AND%20SRC:MED&resulttype=core&format=json

17 March 2020

author name string

David Suarez

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27366212%20AND%20SRC:MED&resulttype=core&format=json

17 March 2020

language of work or name

English

0 references

publication date

16 December 2015

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27366212%20AND%20SRC:MED&resulttype=core&format=json

Therapeutic Advances in Gastroenterology

17 March 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27366212%20AND%20SRC:MED&resulttype=core&format=json

17 March 2020

volume

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27366212%20AND%20SRC:MED&resulttype=core&format=json

17 March 2020

issue

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27366212%20AND%20SRC:MED&resulttype=core&format=json

17 March 2020

page(s)

437-448

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27366212%20AND%20SRC:MED&resulttype=core&format=json

Systematic review and meta-analysis: susceptibility-guided versus empirical antibiotic treatment for Helicobacter pylori infection

17 March 2020

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4913327

Meta-analysis of Observational Studies in Epidemiology: A Proposal for Reporting

7 April 2017

2 references

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4913327

7 April 2017

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4913327

Management of Helicobacter pylori infection--the Maastricht IV/ Florence Consensus Report

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4913327

Rifabutin-based high-dose proton-pump inhibitor and amoxicillin triple regimen as the rescue treatment for Helicobacter pylori

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4913327

Efficacy of tailored Helicobacter pylori eradication treatment based on clarithromycin susceptibility and maintenance of acid secretion

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4913327

Efficacy of genotypic resistance-guided sequential therapy in the third-line treatment of refractory Helicobacter pylori infection: a multicentre clinical trial.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4913327

Helicobacter pylori eradication in Western Australia using novel quadruple therapy combinations.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4913327

Efficacy of a therapeutic strategy for eradication of Helicobacter pylori infection.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4913327

Clinical practice. Helicobacter pylori infection

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4913327

Quadruple rescue therapy for Helicobacter pylori infection after two treatment failures

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4913327

A clinical practice viewpoint: to culture or not to culture Helicobacter pylori?

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4913327

Helicobacter pylori eradication in patients with peptic ulcer after two treatment failures: a prospective culture-guided study

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4913327

Antibiotic-resistant Helicobacter pylori strains in Portuguese children

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4913327

A third-line levofloxacin-based rescue therapy for Helicobacter pylori eradication

31 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4913327

Pretreatment antimicrobial-susceptibility testing in the eradication of H. pylori infection

31 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4913327

Furazolidone combination therapies for Helicobacter pylori infection in the United States.

31 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4913327

High efficacy of 1-week doxycycline- and amoxicillin-based quadruple regimen in a culture-guided, third-line treatment approach for Helicobacter pylori infection

31 May 2018

1 reference

https://api.crossref.org/works/10.1177%2F1756283X15621229

Usefulness of antimicrobial susceptibility in the eradication of Helicobacter pylori.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1756283X15621229

Culture-based selection therapy for patients who did not respond to previous treatment for Helicobacter pylori infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1756283X15621229

Pharmacogenomics-based tailored versus standard therapeutic regimen for eradication of H. pylori

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1756283X15621229

Efficacy of a multistep strategy for Helicobacter pylori eradication.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1756283X15621229

Third-line rescue therapy with levofloxacin after two H. pylori treatment failures

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1756283X15621229

Third-line rescue therapy with bismuth-containing quadruple regimen after failure of two treatments (with clarithromycin and levofloxacin) for H. pylori infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1756283X15621229

Tailored eradication therapy based on fecal Helicobacter pylori clarithromycin sensitivities

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1756283X15621229

Second‐line treatment for failure to eradicate Helicobacter pylori: a randomized trial comparing four treatment strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1756283X15621229

Eradication of Helicobacter pylori according to 23S ribosomal RNA point mutations associated with clarithromycin resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1756283X15621229

Helicobacter pylori resistance to antibiotics in Europe and its relationship to antibiotic consumption

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1756283X15621229

Is antimicrobial susceptibility testing necessary before second-line treatment for Helicobacter pylori infection?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1756283X15621229

Role of antibiotic sensitivity testing before first-line Helicobacter pylori eradication treatments.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1756283X15621229

Pretreatment antimicrobial susceptibility testing is cost saving in the eradication of Helicobacter pylori

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1756283X15621229

Role of antimicrobial susceptibility testing on efficacy of triple therapy in Helicobacter pylori eradication

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1756283X15621229

Efficacy and tolerability of a third-line, levofloxacin-based, 10-day sequential therapy in curing resistant Helicobacter pylori infection.

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4913327

Susceptibility to antibiotics and drug metabolism in patients with H. pylori infection refractory to the initial treatment--therapeutic strategy based on susceptibility to CAM and CYP2C19 polymorphism

28 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4913327

The effect of culture results for Helicobacter pylori on the choice of treatment following failure of initial eradication

28 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4913327

Efficacy of rifabutin-based triple therapy in Helicobacter pylori infected patients after two standard treatments

28 November 2018

1 reference

12 December 2020

Susceptibility-guided vs. empiric retreatment of Helicobacter pylori infection after treatment failure

1 reference

12 December 2020

Cure of Helicobacter pylori infection after failed primary treatment: one-center results from 120 patients

1 reference

12 December 2020

Role of the preliminary susceptibility testing for initial and after failed therapy of Helicobacter pylori infection with levofloxacin, amoxicillin, and esomeprazole

1 reference

12 December 2020

Third line treatment for Helicobacter pylori: a prospective, culture-guided study in peptic ulcer patients

1 reference

12 December 2020

Nonbismuth Quadruple (Concomitant) Therapy: Empirical and Tailored Efficacy versus Standard Triple Therapy for Clarithromycin-Susceptible Helicobacter pylori and versus Sequential Therapy for Clarithromycin-Resistant Strains

1 reference

12 December 2020

Costs of diagnosis and treatment of Helicobacter pylori infection: when does choosing the treatment regimen based on susceptibility testing become cost effective?

1 reference

12 December 2020

Identifiers

DOI

10.1177/1756283X15621229

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27366212%20AND%20SRC:MED&resulttype=core&format=json

17 March 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27366212%20AND%20SRC:MED&resulttype=core&format=json

17 March 2020

1 reference